Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05459571 · ClinicalTrials.gov registry record · Phase 2
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
A Phase 2 study of Relapsed or Refractory Large B-cell Lymphoma, sponsored by Kite, A Gilead Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 16
- Study locations
NCT05459571 is a Phase 2 study of Relapsed or Refractory Large B-cell Lymphoma that has completed, run by Kite, A Gilead Company. The registered enrollment target is 35 participants. The trial reports 16 study locations across 11 states.
The verdict
NCT05459571, a Phase 2 study of Relapsed or Refractory Large B-cell Lymphoma, has completed, sponsored by Kite, A Gilead Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 16
- Study locations
Study Summary
The goal of this clinical study is to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Dexamethasone
- BIOLOGICAL Axicabtagene Ciloleucel
Study Locations (16)
Virginia
- University of Virginia Health System - Charlottesville
- Virginia Oncology Associates - Norfolk
- Virginia Commonwealth University - Richmond
California
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) - Duarte
- UCLA - Los Angeles
Tennessee
- Tennessee Oncology, PLLC - Nashville
- Henry-Joyce Cancer Clinic - Nashville
Utah
- Intermountain Healthcare - Murray
- Huntsman Cancer Institute, University of Utah - Salt Lake City
Colorado
- Colorado Blood Cancer Institute - Denver
Maryland
- University of Maryland Greenebaum Comprehensive Cancer Center - Baltimore
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
New Jersey
- John Theurer Cancer Center at Hackensack University Medical Center - Hackensack
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2022-08-09 |
| Est. Completion | 2025-11-24 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05459571
The ClinicalTrials.gov registry entry for NCT05459571 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Relapsed or Refractory Large B-cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT05459571 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Virginia, California, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05459571 about?
NCT05459571 is a clinical study titled "Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma". The goal of this clinical study is to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.
What is the current status of trial NCT05459571?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2022-08-09. Estimated completion is 2025-11-24.
What conditions does trial NCT05459571 study?
This clinical trial studies the following conditions: Relapsed or Refractory Large B-cell Lymphoma.
What interventions are being tested in trial NCT05459571?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Dexamethasone (DRUG), Axicabtagene Ciloleucel (BIOLOGICAL).
Who is sponsoring clinical trial NCT05459571?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05459571 being conducted?
This trial has 16 study locations across California, Colorado, Maryland, Michigan, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsed or Refractory Large B-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.